Peptide Lab HQ Research Guide
Cagrilintide
A research-focused compound profile covering Cagrilintide identity, long-acting amylin analogue research, amylin receptor pathway models, appetite-signaling research context, concentration reference, reconstitution reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Cagrilintide |
|---|---|
| Common Research Names | Cagrilintide, NN9838, AM833, long-acting amylin analogue |
| Compound Type | Long-acting acylated amylin analogue / metabolic research peptide |
| CAS Number | 1415456-99-3 |
| PubChem CID | 171397054 |
| Peptide Class | Modified amylin-family peptide with long-acting acylation and disulfide-bridge structure |
| Structural Context | Pramlintide-derived / amylin-based analogue with lipid modification; exact sequence notation should be verified against supplier COA. |
| Molecular Formula | C₁₉₄H₃₁₂N₅₄O₅₉S₂; verify against supplier COA |
| Molecular Weight | Approximately 4409 g/mol; verify against supplier COA |
| Research Category | Amylin receptor signaling, calcitonin receptor pathway context, appetite signaling, satiety research, gastric-emptying research, metabolic pathway research, and body-weight model research |
| Receptor Context | Studied in relation to amylin receptor complexes and calcitonin receptor pathway activity. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Cagrilintide is commonly discussed in controlled research models involving long-acting amylin analogue activity, amylin receptor signaling, calcitonin receptor pathway context, appetite-signaling pathways, satiety response, gastric-emptying research, body-weight models, and metabolic-marker documentation.
Amylin Analogue Research
Cagrilintide is studied as a long-acting amylin analogue designed for extended activity compared with native amylin.
Appetite-Signaling Models
Used in research involving satiety signaling, food-intake regulation, appetite-response pathways, and central appetite-control models.
Body-Weight Research
Cagrilintide has been evaluated in clinical research involving body-weight change, waist-circumference change, and metabolic-response documentation.
Amylin / Calcitonin Receptor Context
Structural research has evaluated cagrilintide binding across amylin receptor complexes and calcitonin receptor systems.
Combination Research Context
Cagrilintide is commonly discussed in combination with semaglutide as CagriSema, where amylin analogue and GLP-1 receptor pathways are studied together.
Metabolic Marker Research
Research contexts include body-weight change, glycemic-marker tracking, gastrointestinal tolerability, and longer metabolic-study windows.
Research Scope
These applications are provided for educational and research-reference purposes only. Research outcomes may vary based on compound form, purity, concentration, model type, route, timing, receptor expression, metabolic status, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Select Reference Vial
Select a vial size to update the concentration, U-100 unit references, and frequency table below.
Quick Reference Summary
| Reference Vial | 5 mg Cagrilintide |
|---|---|
| Primary Solution Volume | 2.0 mL bacteriostatic water |
| Primary Concentration | 2.5 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 2.5 mg/mL, 1 unit equals 0.025 mg / 25 mcg Cagrilintide. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Verify complete dissolution before recording the final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Cagrilintide, long-acting amylin analogue research compound | Cagrilintide is commonly discussed as a lipidated, long-acting amylin analogue in calcitonin-family receptor, appetite, satiety, and metabolic-marker research contexts. |
| Amylin / Calcitonin-Family Receptor Research | Amylin and calcitonin-family receptor pathway context | Commonly discussed in amylin receptor, calcitonin receptor, receptor-binding, satiety signaling, and neuroendocrine-metabolic pathway research. |
| Appetite / Satiety Research Context | Clinical-study and model-dependent context | Cagrilintide has been discussed in research involving appetite-response markers, satiety signaling, food-intake behavior, body-weight marker trends, and energy-balance research models. |
| Glucose / Gastric-Emptying Research | Model-dependent metabolic-marker tracking | Amylin-analogue research commonly includes glucose-handling, gastric-emptying context, pancreatic hormone signaling, insulin-associated markers, and metabolic-homeostasis endpoints. |
| CagriSema Combination Research | Cagrilintide + semaglutide clinical-study context only | Cagrilintide has been studied in combination with semaglutide in metabolic and body-weight marker research. These clinical-study contexts are not research-chemical dosing standards. |
| Public Protocol-Style Reference | Microgram-to-milligram reference examples | Public protocol-style references commonly describe Cagrilintide in microgram-to-milligram examples depending on the research model and preparation format. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, clinical-study references, public protocol-style references, wellness protocols, or public dosing pages should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 5 mg | 2.0 mL | 2.5 mg/mL |
| 10 mg | 2.0 mL | 5 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 2.5 mg/mL | U-100 Unit Reference | Approx. References per 5 mg Vial |
|---|---|---|---|
| 50 mcg | 0.02 mL | 2 units | 100 |
| 0.1 mg / 100 mcg | 0.04 mL | 4 units | 50 |
| 0.25 mg / 250 mcg | 0.10 mL | 10 units | 20 |
| 0.5 mg / 500 mcg | 0.20 mL | 20 units | 10 |
| 1 mg / 1000 mcg | 0.40 mL | 40 units | 5 |
| 2 mg / 2000 mcg | 0.80 mL | 80 units | 2.5 |
| 5 mg / 5000 mcg | 2.00 mL | 200 units | 1 |
| 10 mg / 10000 mcg | 4.00 mL | 400 units | 0.5 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Microgram Reference | Calculation reference only | 50 mcg reference amount | 2 units / 0.02 mL |
| Standard Microgram Reference | Calculation reference only | 0.1 mg reference amount | 4 units / 0.04 mL |
| Low Milligram Conversion Example | Public protocol-style reference, not a clinical dosing standard | 250 mcg reference amount | 10 units / 0.10 mL |
| Mid-Range Conversion Example | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 20 units / 0.20 mL |
| Upper Conversion Example | Calculation reference only | 1 mg reference amount | 40 units / 0.40 mL |
| High Conversion Example | Calculation reference only | 2 mg reference amount | 80 units / 0.80 mL |
| 5 mg Preparation Reference | Preparation-level calculation reference | 5 mg reference amount | 200 units / 2.00 mL |
| 10 mg Preparation Reference | Preparation-level calculation reference | 10 mg reference amount | 400 units / 4.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Receptor Observation Window | 24–72 hours | May be used for amylin receptor, calcitonin-family receptor, receptor-binding, intracellular signaling, or pathway-response documentation depending on the model. |
| Acute Metabolic Observation Window | Single session to several days | Used for short-term satiety signaling, glucose-marker comparison, gastric-emptying context, appetite-response markers, or early pathway tracking depending on the research design. |
| Short Research Window | 1–4 weeks | May be used for early controlled observation involving food-intake behavior, metabolic markers, glucose-handling markers, appetite-response markers, or dose-ranging model documentation. |
| Standard Protocol-Style Window | 4–12 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 12–24 weeks or longer | Used when longer documentation is needed for body-weight, appetite-response, glycemic-marker, gastric-emptying, cardiometabolic, or follow-up marker tracking. |
| Follow-Up / Washout | 4–12 weeks | Used to document post-study observations, marker return, delayed response patterns, or return-to-baseline data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Cagrilintide is commonly discussed in long-acting amylin analogue, calcitonin-family receptor, satiety, appetite-response, food-intake behavior, gastric-emptying, glucose-handling, body-weight marker, and metabolic-marker research contexts. The selector above updates calculations for 5 mg and 10 mg vial references, each reconstituted with 2.0 mL bacteriostatic water. Published study references, clinical-study contexts, combination references with semaglutide, and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Cagrilintide is commonly discussed in research involving long-acting amylin analogue activity, appetite signaling, satiety response, food-intake reduction models, body-weight research, amylin receptor signaling, calcitonin receptor pathway context, and metabolic-marker documentation.
Study Limitations
Cagrilintide research includes clinical dose-finding studies, structural receptor research, metabolic research, and combination studies with semaglutide. Findings should be interpreted according to study design, route, dose, escalation schedule, metabolic status, and endpoint selection.
Safety Considerations
Research discussion should account for gastrointestinal response, nausea, constipation, diarrhea, administration-site reactions, hypoglycemia monitoring in combination contexts, peptide purity, sterility documentation, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.